Capricor Therapeutics, one of the most controversial Biotech stocks of the past 12 months is nearing their imminent approval, in the face of many short sellers pushing retail short interest of float above 200%, once again, this time with already released positive clinical data.
Upcoming Dates:
7/29 - ADCOMM - Public link with YouTube access
8/22 - Targeted PDUFA Date
September - Expected Outcome of OSC from Nippon Distribution
New Headquarters & Production facility for integrated productions and drug rollout.
I am long, 250,000 shares, and will hold through all three dates that are inbound. Meeting both endpoints with clinical significance is enough for me to block out the noise of the desperate shorts who still cry wolf.
See OPPENHEIMER latest Analyst Report from 7/22